Vor Biopharma Inc.
VOR
$7.53
-$0.15-1.95%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 501.42% | -63.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -88.04% | 631.58% | |||
| Operating Income | 88.04% | -631.58% | |||
| Income Before Tax | 48.36% | -4,744.15% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 48.36% | -4,744.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 48.36% | -4,744.15% | |||
| EBIT | 88.04% | -631.58% | |||
| EBITDA | 87.94% | -643.90% | |||
| EPS Basic | 51.59% | -4,726.83% | |||
| Normalized Basic EPS | 50.56% | -4,632.55% | |||
| EPS Diluted | 51.59% | -4,726.83% | |||
| Normalized Diluted EPS | 50.56% | -4,632.55% | |||
| Average Basic Shares Outstanding | 6.68% | 0.36% | |||
| Average Diluted Shares Outstanding | 6.68% | 0.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||